But 2024 was a relatively quiet year for smartwatches, during which iterative updates reigned supreme. That happens in a ...

Oura announced today that it completed a $200 million Series D funding round with investment from Dexcom (Nasdaq:DXCM).

The investment comes as part of a new health monitoring partnership between the continuous glucose monitor (CGM) maker and Oura, the maker of smart ring technology. Fidelity Management & Research Co.

Smart ring maker Oura announced on Thursday that it has closed a $200 million Series D funding round, bringing the company’s ...

Dexcom’s OTC glucose biosensor Stelo is the first product to use the GenAI platform for improved weekly insights.

Oura Ring 4 in six colors. ŌURA was founded in Finland in 2013—before Apple launched ... The latest funding round was led by ...

The $200 million Series D investment gives the smart ring maker a valuation of $5.2 billion. The past year has been an active one for Ōura. It acquired Sparta Science and Veri, launched its Gen 4 ring ...

Oura’s series D round of funding included participation from Fidelity Management & Research company and glucose monitoring company Dexcom. The $200 million in funding brings Oura’s total valuation to ...

Finnish health tech firm Oura has closed a $200M Series D funding round that boosts its market valuation to $5.2B. The smart ...

Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its glucose ...

Oura Health Oy, the maker of health-tracking smart device Oura Ring, said today it has raised $200 million in a new late-stage funding, doubling its valuation since 2022 to $5.2 billion. Fidelity ...

(NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their ...